علاج متلازمة الكارسينوئيد في أورام الغدد الصماء العصبية للأمعاء الدقيقة عند فشل مناهج السوماتوستاتين

References

DOI: 10.1111/jne.13423

It is important to note that patients suffering from CS are treated differently from patients with non-functioning Si-NET.

Some patients present with specific symptoms of the carcinoid syndrome (CS) due to secretion of biologically active compounds such as serotonin and tachykinins or are discovered during surgery for intestinal obstruction or bleeding.

In patients with refractory CS and predominant diarrhoea, telotristat ethyl should be added to SSA (Recommendation A-1a).

SSA dose escalation can be considered in patients with refractory CS (Recommendation A-3b) or alternatively addition of IFN-α (Recommendation B-2b).

Telotristat ethyl, an oral inhibitor of the serotonin synthesis, significantly reduced diarrhoea and 5-HIAA levels in patients with refractory CS in two randomised placebo-controlled trials.